Literature DB >> 27755362

Long-term Incidence and Degree of Sensorineural Hearing Loss in Otosclerosis.

Reuven Ishai1, Christopher F Halpin, Jennifer J Shin, Michael J McKenna, Alicia M Quesnel.   

Abstract

OBJECTIVES: 1) To evaluate the long-term incidence and degree of the sensorineural component of hearing loss (SNHL) in patients with otosclerosis after accounting for expected age-related hearing loss. 2) To identify variables that might predict development of sensorineural hearing loss due to otosclerosis. STUDY
DESIGN: Retrospective audiometric database and chart review.
SETTING: Tertiary referral center. PATIENTS: Consecutive patients with otosclerosis observed between 1994 and 2004, with ≥10 years follow-up, excluding patients with postoperative hearing loss or surgery before the initial audiogram. INTERVENTION: Bone conduction (BC) thresholds at 0.5, 1, 2, and 4 kHz and Word Recognition. MAIN OUTCOME MEASURE: BC threshold change (BCTC) over ≥10 years minus estimated age-related threshold change (ARTC) specific to age and sex for each patient (based on ISO 7029 reference population).
RESULTS: Three-hundred fifty-seven ears (290 patients) met study criteria, including 217 ears that had undergone stapedectomy during the study period. Mean follow-up was 14.0 years. The average BCTC after subtracting estimated ARTC was 4.6, 2.6, 3, and 2.7 dB for 0.5, 1, 2, and 4 kHz frequencies, respectively. However, 34% of ears (122 ears) had clinically significant progression of SNHL during the study period (>10 dB BCTC beyond expected ARTC at ≥2 frequencies). Multivariate analysis demonstrated that the probability of developing clinically significant SNHL was higher for women (odds ratio 1.86, p = 0.018) and lower for operated patients (odds ratio 0.46, p = 0.002).
CONCLUSION: The average long-term sensorineural hearing loss due to otosclerosis was statistically significantly more than for age alone at each frequency, but these average values (from 2.6 to 4.6 dB for tested frequencies) were clinically insignificant. Approximately one-third of patients with otosclerosis demonstrated a clinically significant progression of the sensorineural component of hearing loss, with the average BCTC above expected age-related changes ranging from 10.2 to 14.6 dB for tested frequencies among this subgroup.

Entities:  

Mesh:

Year:  2016        PMID: 27755362     DOI: 10.1097/MAO.0000000000001234

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  6 in total

1.  Computed Tomography Density as a Bio-marker for Histologic Grade of Otosclerosis: A Human Temporal Bone Pathology Study.

Authors:  Alicia M Quesnel; Reuven Ishai; Timothy Meehan; Jennifer T O'Malley; Renee Mitchell; Jennifer J Shin; Hugh D Curtin; Joseph B Nadol; Michael J McKenna; Amy F Juliano
Journal:  Otol Neurotol       Date:  2022-07-01       Impact factor: 2.619

2.  Third-generation bisphosphonates for cochlear otosclerosis stabilizes sensorineural hearing loss in long-term follow-up.

Authors:  Taha A Jan; Aaron K Remenschneider; Christopher Halpin; Margaret Seton; Michael J McKenna; Alicia M Quesnel
Journal:  Laryngoscope Investig Otolaryngol       Date:  2017-09-21

3.  Stability of computed tomography densitometry in patients with otosclerosis:a two-year follow-up.

Authors:  Yanqing Fang; Wei Chen; Liu-Jie Ren; Sebastian Kiehn; Yilai Shu; Bing Chen
Journal:  J Otol       Date:  2021-11-08

Review 4.  Bisphosphonate therapy in otosclerosis: A scoping review.

Authors:  René E Zimmerer; Robert E Africa; Zack K Westenhaver; Brian J McKinnon
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-01-06

5.  Evidence of distinct RELN and TGFB1 genetic associations in familial and non-familial otosclerosis in a British population.

Authors:  Andrew J Mowat; Michael Crompton; Joanna L Ziff; Christopher P Aldren; Jeremy A Lavy; Shakeel R Saeed; Sally J Dawson
Journal:  Hum Genet       Date:  2018-05-04       Impact factor: 4.132

6.  Hearing impairment in young and middle-aged septicemia survivors.

Authors:  Chun-Gu Cheng; Wu-Chien Chien; Hung-Che Lin; Hui-Chen Lin; Chi-Hsiang Chung; Chun-An Cheng
Journal:  Medicine (Baltimore)       Date:  2020-07-17       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.